How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

1 Recommendations

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about spesolimab

2.1

Spesolimab (Spevigo, Boehringer Ingelheim) is indicated 'for the treatment of flares in adult patients with generalised pustular psoriasis'.

Dosage in the marketing authorisation

Price

2.3

The list price for spesolimab is £15,000 for 2 450‑mg vials (excluding VAT; BNF, accessed December 2024).

2.4

The company has a commercial arrangement (simple discount patient access scheme), which if it had been recommended, would have made. spesolimab available to the NHS with a discount.